31.89

0.47% 0.15

After Hours: 32.03 0.14 +0.44%

Teva Pharmaceutical Industries Ltd Adr (TEVA)

Overview News Price History Option Chain Financials Why TEVA Down? Discussions Forecast Stock Split Dividend History

Teva Pharmaceutical Industries Ltd Adr stock is traded at $31.89, with a volume of 2.62M. It is up +0.47% in the last 24 hours and up +21.16% over the past month. Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.

Previous Close:

$31.74

Open:

$31.53

24h Volume:

2.62M

Relative Volume:

0.24

Market Cap:

$36.59B

Revenue:

$16.88B

Net Income/Loss:

$666.71M

P/E Ratio:

52.01

EPS:

0.6132

Net Cash Flow:

$251.19M

1W Performance:

+5.07%

1M Performance:

+21.16%

6M Performance:

+92.57%

1Y Performance:

+40.98%

1-Day Range:

$31.47

$31.89

1-Week Range:

$30.50

$31.99

52-Week Range:

$12.46

$31.99

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Company Profile

Name

Teva Pharmaceutical Industries Ltd Adr

Sector

Healthcare (1131)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

972 (3) 914-8213

Address

TEVA PHARMACEUTICAL INDUSTRIES LIMITED, TEL AVIV

Employee

35,686

Twitter

@TevaUSA

Next Earnings Date

2025-01-29

Latest SEC Filings

TEVA's Discussions on Twitter

Compare TEVA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
TEVA Teva Pharmaceutical Industries Ltd Adr	31.89	36.41B	16.88B	666.71M	251.19M	0.6132
ZTS Zoetis Inc	126.23	55.30B	9.40B	2.65B	2.24B	5.935
TAK Takeda Pharmaceutical Co Adr	15.65	49.22B	29.63B	260.53M	5.51B	0.0788
HLN Haleon Plc Adr	10.13	44.97B	14.26B	1.98B	2.47B	0.4327
UTHR United Therapeutics Corp	507.16	22.16B	3.08B	1.24B	1.07B	25.61

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Overweight
Dec-05-25	Initiated	Scotiabank	Sector Outperform
Jun-06-25	Initiated	Goldman	Buy
May-28-25	Initiated	Truist	Buy
May-12-25	Upgrade	JP Morgan	Neutral → Overweight
Jul-10-24	Upgrade	Argus	Hold → Buy
Mar-08-24	Upgrade	JP Morgan	Underweight → Neutral
Feb-12-24	Upgrade	Piper Sandler	Neutral → Overweight
Jan-23-24	Upgrade	Jefferies	Hold → Buy
Jan-03-24	Upgrade	Piper Sandler	Underweight → Neutral
Dec-18-23	Initiated	HSBC Securities	Buy
Nov-27-23	Upgrade	UBS	Neutral → Buy
Jul-06-23	Upgrade	UBS	Sell → Neutral
May-25-23	Initiated	Morgan Stanley	Equal-Weight
May-18-23	Upgrade	Evercore ISI	In-line → Outperform
Jan-19-23	Downgrade	Jefferies	Buy → Hold
Nov-14-22	Downgrade	JP Morgan	Neutral → Underweight
Nov-04-22	Downgrade	UBS	Neutral → Sell
Oct-21-22	Resumed	Jefferies	Buy
Aug-05-22	Upgrade	BofA Securities	Neutral → Buy
Jun-14-22	Resumed	UBS	Neutral
May-17-22	Upgrade	BofA Securities	Underperform → Neutral
May-04-22	Downgrade	Piper Sandler	Neutral → Underweight
Apr-05-22	Upgrade	Barclays	Equal Weight → Overweight
Mar-25-22	Upgrade	Bernstein	Mkt Perform → Outperform
Jan-27-22	Downgrade	Argus	Buy → Hold
Oct-28-21	Downgrade	Raymond James	Outperform → Mkt Perform
May-04-21	Downgrade	UBS	Buy → Neutral
Apr-07-21	Resumed	RBC Capital Mkts	Sector Perform
Nov-25-20	Initiated	Oppenheimer	Perform
Aug-06-20	Upgrade	Barclays	Underweight → Equal Weight
Jul-27-20	Resumed	Goldman	Neutral
Jun-01-20	Upgrade	SunTrust	Hold → Buy
Apr-24-20	Resumed	Citigroup	Neutral
Apr-06-20	Upgrade	UBS	Neutral → Buy
Feb-24-20	Downgrade	Edward Jones	Hold → Sell
Nov-12-19	Upgrade	JP Morgan	Underweight → Neutral
Oct-17-19	Upgrade	Gabelli & Co	Hold → Buy
Aug-07-19	Downgrade	Evercore ISI	Outperform → In-line
Jul-19-19	Initiated	Wolfe Research	Peer Perform
Jul-15-19	Downgrade	Morgan Stanley	Equal-Weight → Underweight
Jul-10-19	Resumed	Credit Suisse	Neutral
Jul-05-19	Upgrade	Argus	Hold → Buy
Jun-11-19	Initiated	Barclays	Underweight
Jun-03-19	Upgrade	Oppenheimer	Perform → Outperform
May-30-19	Downgrade	BofA/Merrill	Buy → Underperform
May-28-19	Downgrade	UBS	Buy → Neutral
Mar-20-19	Initiated	SunTrust	Hold
Mar-07-19	Resumed	UBS	Buy

View All

Teva Pharmaceutical Industries Ltd Adr Stock (TEVA) Latest News

02:03 AM

Why a $34 Million Teva Stock Position Signals Confidence in a Long Repair Story - The Motley Fool

02:03 AM

Dec 22, 2025

J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play - Finviz

Dec 22, 2025

Dec 19, 2025

Teva Pharma stock hits 52-week high at 30.45 USD - Investing.com India

Dec 19, 2025

Dec 18, 2025

Teva (TEVA): Assessing Valuation After a 65% Three‑Month Share Price Surge - Sahm

Dec 18, 2025

Dec 17, 2025

BofA Raises Teva Pharmaceuticals Industries Limited (TEVA) Target to $32 as Barclays Initiates Overweight - Finviz

Dec 17, 2025

Dec 16, 2025

FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? - Finviz

Dec 16, 2025

Dec 14, 2025

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead? - Finviz

Dec 14, 2025

Has Teva’s 80% One Year Surge Run Ahead of Its Fundamental Valuation in 2025? - Sahm

Dec 14, 2025

Dec 13, 2025

Teva to Host Conference Call to Discuss Fourth Quarter 2025 Financial Results at 8 a.m. ET on January 28, 2026 - Sahm

Dec 13, 2025

Dec 12, 2025

Teva Releases Q4 2025 Aide Memoire - Sahm

Dec 12, 2025

Dec 11, 2025

Teva (NYSE:TEVA) Valuation Check After New Schizophrenia Drug Filing and Growing Growth Optimism - Sahm

Dec 11, 2025

Teva’s FDA Filing For Once-Monthly Schizophrenia Drug Might Change The Case For Investing In TEVA - Sahm

Dec 11, 2025

Teva Pharma stock hits 52-week high at 29.81 USD By Investing.com - Investing.com Nigeria

Dec 11, 2025

Teva (NYSE:TEVA) Valuation Check After Strong Q3, Margin Targets and Deleveraging Drive a Sharp Share Price Rebound - Sahm

Dec 04, 2025

Dec 01, 2025

Teva Shares Rise Following Launch of First Generic GLP-1 Weight Loss Drug - MSN

Dec 01, 2025

Nov 30, 2025

30% of Billionaire Stanley Druckenmiller's Portfolio Is Invested in These 3 Biotech Stocks - Finviz

Nov 30, 2025

Nov 28, 2025

Teva to Present at the 8th Annual Evercore Healthcare Conference, the Piper Sandler 37th Annual Healthcare Conference and Citi’s 2025 Global Healthcare Conference in December - Sahm

Nov 28, 2025

Nov 27, 2025

Is the Market Bullish or Bearish on Teva Pharmaceutical Industries Ltd? - Sahm

Nov 27, 2025

Nov 26, 2025

Teva stock hits 52-week high at 26.38 USD - Investing.com

Nov 26, 2025

Nov 25, 2025

Teva Rise Innovation Platform Might Change The Case For Investing In Teva Pharmaceutical Industries (TEVA) - Sahm

Nov 25, 2025

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva® - Sahm

Nov 25, 2025

Nov 19, 2025

Teva Launches Rise: A Global Open Innovation Platform to Accelerate AI, Industry 4.0, Smart Manufacturing, Digital Health and Biotech Breakthroughs for Pharma's Biggest Challenges - Finviz

Nov 19, 2025

Nov 17, 2025